Company profile: Estrella Biopharma
1.1 - Company Overview
Company description
- Provider of proprietary CD19-Redirected ARTEMIS T-cell therapies for cancer, designed to treat CD19-positive blood cancers with reduced risk of CRS and neurotoxicity. Offerings include a Mark-and-Kill approach using an oncolytic virus to label solid tumors for targeting by ARTEMIS T Cells, EB104 (CD19/CD22) for blood cancers, and EB103 combined with an oncolytic virus for solid tumors.
Products and services
- CD19-Redirected ARTEMIS T Cells: Proprietary T-cell therapy engineered to treat CD19-positive blood cancers with reduced risk of cytokine release syndrome (CRS) and neurotoxicity
- EB104 (CD19/CD22): Dual-targeted T-cell therapy under development for treating blood cancers by engaging CD19 and CD22
- EB103 + Oncolytic Virus: Combination therapy for solid tumors pairing ARTEMIS T Cells with an oncolytic virus that labels tumors with CD19 for targeting by ARTEMIS T Cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Estrella Biopharma
Oxford BioTherapeutics
HQ: United Kingdom
Website
- Description: Provider of targeted cancer medicines and companion diagnostics for selected antibody programs, developing a broad pipeline of novel antibody therapeutics using its OGAP (Oxford Genome Anatomy Project) platform, supported by strategic partnerships with leading antibody companies including Medarex, Biosite and Amgen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford BioTherapeutics company profile →
Incyte
HQ: United States
Website
- Description: Provider of drug discovery and development focused on building a proprietary pipeline of novel small molecule drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Incyte company profile →
Alpheus Medical
HQ: United States
Website
- Description: Provider of a non-invasive sonodynamic therapy platform for solid body cancers that uses ultrasound to activate a cancer-targeting drug, including an SDT platform for outpatient treatment of recurrent high-grade gliomas and CV-01, an investigational drug-device using low-intensity, large-field ultrasound to target cancer cells across the brain hemisphere; CV-01 is in Phase 1 clinical trials for recurrent glioblastoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpheus Medical company profile →
Northwest Biotherapeutics
HQ: United States
Website
- Description: Provider of cancer immunotherapy products, focused on developing and commercializing personalized vaccine candidates: DCVax-L for newly diagnosed glioblastoma multiforme (GBM) in a Phase III trial; DCVax-Direct for direct injection into inoperable solid tumors in a Phase I/II trial; and DCVax-Prostate targeting late-stage, hormone-independent prostate cancer using a proprietary PSMA antigen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Northwest Biotherapeutics company profile →
LadRx
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics leveraging LADR (Linker Activated Drug Release) technology to bind anti-cancer molecules to albumin and release cytotoxic payloads at tumors, enabling higher doses with minimized off-target toxicity. Portfolio includes Aldoxorubicin, next-generation LADR-7, and Arimoclomol to amplify heat-shock proteins against protein misfolding, aggregation, and lysosomal dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LadRx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Estrella Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Estrella Biopharma
2.2 - Growth funds investing in similar companies to Estrella Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Estrella Biopharma
4.2 - Public trading comparable groups for Estrella Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →